|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 2021 L Street NW, Suite 900 |
Address2 |
|
| City | WASHINGTON |
State | DC |
Zip Code | 20036 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 59171-12
|
||||||||
|
6. House ID# 352060000
|
||||||||
| TYPE OF REPORT | 8. Year | 2024 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Suzanne M. Leous |
Date | 1/17/2025 2:49:25 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Public health program funding
Federal research funding
Advanced Research Projects Agency for Health (ARPA-H)
FY 2025 NIH funding
FY 2025 AHRQ funding
FY 2025 CDC funding
FY 2025 funding for CDC Sickle Cell Data Collection program
FY 2025 funding for HRSA Sickle Cell Disease Treatment Demonstration program and Sickle Cell Disease Newborn Screening program
FY 2025 funding for Pediatric Specialty Loan Repayment Program (PSLRP, Public Health Service Act Sec. 775)
FY 2025 funding for Defense Health Research Programs, including the Congressionally Directed Medical Research Programs (CDMRP)
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025 (H.R. 9029/S. 4942)
Department of Defense Appropriations Act, 2025(H.R. 8774/S. 4921)
FY 2025 Further Continuing Appropriations Act (through 3/14/2025)(H.R.10515, H.R. 10545)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Disease Control & Prevention (CDC), Health & Human Services - Dept of (HHS), Natl Institutes of Health (NIH), Health Resources & Services Administration (HRSA), Defense - Dept of (DOD), Food & Drug Administration (FDA), Agency for Healthcare Research & Quality (AHRQ), Office of Management & Budget (OMB)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tracy |
Roades |
|
|
|
Stephanie |
Kaplan |
|
|
|
Suzanne |
Leous |
MPA |
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Sickle cell disease/trait issues
Hematology/oncology treatment issues
Hematology/oncology drug research and approval issues
General hematology public health and research issues
Open access policy for peer reviewed research journals
Issues impacting blood supply shortages/safety
Issues impacting delivery of bone marrow, peripheral blood, and cord blood
Clinical trials regulations and coverage
Issues related to diversity, equity, and inclusion (DEI) in hematology research, practice, and training
Advanced Research Projects Agency for Health (ARPA-H)
White House Initiative on Womens Health Research re: priority research areas
Issues impacting laboratory testing and pediatric reference intervals (PRIs)
Issues impacting laboratory developed tests (LDTs)
Issues impacting drug shortages
House Energy and Commerce Committee proposed framework for NIH reform
FDA guidance impacting hematology
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), President of the U.S., White House Office, Defense - Dept of (DOD)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Tracy |
Roades |
|
|
|
Suzanne |
Leous |
MPA |
|
|
Stephanie |
Kaplan |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Coverage of blood transfusions under Medicare Hospice Benefit
Issues related to CAR-T/cellular and gene therapies
Implementation of the Medicare Access and CHIP Reauthorization Act pf 2015 (P.L. 114-10)
Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148)
CMS national coverage determinations
Medicaid coverage for sickle cell disease
Issues related to telemedicine/telehealth
Sickle cell disease/trait issues, including coverage for cell and gene therapies
Prior authorization
Implementation of the Inflation Reduction Act of 2022 (P.L. 117-169)
Strengthening Medicare for Patients and Providers Act (H.R. 2474)
Resident Physician Shortage Reduction Act (S. 1302)
CONNECT for Health Act (S. 2016/ H.R. 4189)
Improving Access to Transfusion Care for Hospice Patients Act (S. 2186)
Provider Reimbursement Stability Act of 2023 (H.R. 6371)
Telehealth Modernization Act (H.R. 7623 / S. 3967)
Sickle Cell Disease Comprehensive Care Act (H.R. 7432/S. 5097)
dental coverage for Medicare beneficiaries
CMS FY 2025 Hospice proposed rule and payment mechanisms for high intensity palliative care services, including blood transfusions
Improving Seniors' Timely Access to Care Act (S. 4518/S. 4532/H.R. 8702)
Senate Finance Committee Request for Information (RFI) on Medicare physician payment
National Coverage Decision for hematopoietic stem cell transplantation (HSCT) for MDS
Local Coverage Decisions for hematopoietic stem cell transplantation (HSCT) for lymphoma
Duffy-null ICD-10 coding
Local Coverage Decisions for next generation sequencing
Sickle cell disease quality measures
Issues impacting drug shortages
Senate draft Pay PCPs Act
CY 2025 Hospital Outpatient Prospective Payment System (HOPPS) proposed rule
CY 2025 Physician Fee Schedule proposed rule
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Suzanne |
Leous |
MPA |
|
|
Tracy |
Roades |
|
|
|
Stephanie |
Kaplan |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Implementation of the Patient Protection and Affordable Care Act (P.L. 111-148)
Hematology/oncology drug research and approval issues
Implementation of the Food and Drug Administration Safety and Innovation Act (FDASIA) (P.L. 112-144)
Clinical trials regulations and coverage
Issues impacting coverage for hematologic diseases and conditions
Issues related to CAR-T/cellular and gene therapies
Issues impacting blood supply shortages/safety
Issues related to diversity, equity, and inclusion (DEI) in hematology research, practice, and training
Implementation of No Surprises Act (P.L. 116-260)
Sickle cell disease/trait issues
Issues related to maternal health care and abortion access
Issues related to healthcare workforce
Sickle Cell Care Expansion Act (S. 1423/H.R. 3100)
Life Saving Leave Act (H.R. 3024)
Cancer Drug Parity Act (S. 2039/H.R. 6301)
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act (S. 1852/H.R. 3884)
Issues impacting drug shortages
Sickle cell disease quality measures
House discussion draft of Stop Drug Shortages Act
Let Doctors Provide Reproductive Health Care Act (H.R. 2907/S. 1297)
Iron Deficiency Education and Awareness (IDEA) Act (H.R. 6746)
Sickle Cell Disease Treatment Centers Act (H.R. 9872/S. 5226)
Sickle Cell Disease Comprehensive Care Act (H.R. 7432/S. 5097)
FDA guidance impacting hematology
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), Natl Institutes of Health (NIH), Centers For Medicare and Medicaid Services (CMS), Centers For Disease Control & Prevention (CDC)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Suzanne |
Leous |
MPA |
|
|
Tracy |
Roades |
|
|
|
Stephanie |
Kaplan |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |